select trial glp 1 glp-1 Semaglutide and the Heart: clinical insights from the SGLTi and GLP-1 in HF – GLP-1 receptor agonists show promise

Charles EF, Lambert CG, Kerner B

GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1

Chronic alcohol exposure induced gut microbiota dysbiosis and its correlations with neuropsychic behaviors and brain BDNF/Gabra1 changes in mice

For more on its mechanisms and broader recovery effects, see Unlocking the Healing Power of BPC-157

Full catalog Frequently Asked Questions What is the Klow blend

Broken incentives